Search research articles
Contact Us
Filters
Showing results (471-480 of 554) with videos related to
Page
of 56
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2011
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study
Tanya B Dorff, Thomas W Flaig, Catherine M Tangen, et al.
Clinical Genitourinary Cancer
|
July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808
Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
Transboundary and Emerging Diseases
|
November 11, 2017
Rapid and simple detection of foot-and-mouth disease virus: Evaluation of a cartridge-based molecular detection system for use in basic laboratories
K V Goller, V Dill, M Madi, et al.
The Prostate
|
February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America
Anthony M Joshua, Neal D Shore, Fred Saad, et al.
Clinical Chemistry and Laboratory Medicine
|
March 22, 2000
A new liquid homogeneous assay for HDL cholesterol determination evaluated in seven laboratories in Europe and the United States
M Nauck, M S Graziani, J Jarausch, et al.
European Urology
|
May 23, 2018
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
Maxine Sun, Lorenzo Marconi, Tim Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2019
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation
Andres F Correa, Opeyemi Jegede, Naomi B Haas, et al.
Journal for Immunotherapy of Cancer
|
April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2018
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921
Maha Hussain, Catherine M Tangen, Ian M Thompson, et al.
The Oncologist
|
June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma
Kathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
Page
of 56
Search research articles
Search
Showing results (471-480 of 554) with videos related to
Sort By:
Page
of 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2011
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study
Tanya B Dorff, Thomas W Flaig, Catherine M Tangen, et al.
Clinical Genitourinary Cancer
|
July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808
Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
Transboundary and Emerging Diseases
|
November 11, 2017
Rapid and simple detection of foot-and-mouth disease virus: Evaluation of a cartridge-based molecular detection system for use in basic laboratories
K V Goller, V Dill, M Madi, et al.
The Prostate
|
February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America
Anthony M Joshua, Neal D Shore, Fred Saad, et al.
Clinical Chemistry and Laboratory Medicine
|
March 22, 2000
A new liquid homogeneous assay for HDL cholesterol determination evaluated in seven laboratories in Europe and the United States
M Nauck, M S Graziani, J Jarausch, et al.
European Urology
|
May 23, 2018
Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
Maxine Sun, Lorenzo Marconi, Tim Eisen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2019
Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation
Andres F Correa, Opeyemi Jegede, Naomi B Haas, et al.
Journal for Immunotherapy of Cancer
|
April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2018
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921
Maha Hussain, Catherine M Tangen, Ian M Thompson, et al.
The Oncologist
|
June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma
Kathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
Page
of 56